Raising the bar in immuno-oncology

Immuno-oncology (IO) has revolutionized cancer treatment but not for all. Alligator Bioscience is leveraging its antibody technology platform, including its novel RUBY bispecific platform to produce next-generation tumor-directed IO therapies with higher efficacies and lower toxicities.

Go to the profile of Alligator Bioscience
Mar 08, 2019
0
0
Page of
Go to the profile of Alligator Bioscience

Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has 50+ employees. For more information, please visit http://www.alligatorbioscience.com. ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.

No comments yet.